临床研究中心

临床研究中心

临床研究中心

临床试验和研究是宝康醫院临床研究中心实践循证临床研究的关键组成部分。

临床试验为癌症患者测试新的治疗方式,如新的药物、新的治疗组合、新的手术方式或放射治疗,又或者是全新疗法如基因治疗。这些研究和试验的最终目标,就是要找出更多更好的方式来治疗癌症,帮助癌症患者。

临床试验和研究是宝康醫院临床研究中心实践循证临床研究的关键组成部分。

临床试验为癌症患者测试新的治疗方式,如新的药物、新的治疗组合、新的手术方式或放射治疗,又或者是全新疗法如基因治疗。这些研究和试验的最终目标,就是要找出更多更好的方式来治疗癌症,帮助癌症患者。

如果研究证明了一个疗程的有效性,它将会演变成一个能帮助许多患者的标准治疗方式。现今许多有效的标准疗程,如乳癌、结肠癌、直肠癌和童年癌症的治疗方式都是由先前的研究而研发出来的。

参与临床试验的患者能从疗程中获益。参与临床试验的患者能获得癌症专家提供最新的护理。此外,他们也有机会接受新研发的疗程又或者是现今最好的标准疗程来医治他们的癌症。

由于不能保证新研发的疗程不会带来风险或有好的成效,如果疗程被证明能帮助到患者,又或者比标准疗程更有效,参与此临床试验的患者就可是当中第一个受惠者。

研究在治疗进展中扮演着重要的角色。宝康醫院临床研究中心把参与临床试验患者的权益、安全和健康列为优先事项。我们的临床试验除了通过了马来西亚卫生部医学和研究伦理委员会的核准外,我们也遵守本地和国际良好临床实践(GCP)标准,以保护患者的道德利益。

至今,我们的肿瘤科团队已参与了不少临床试验,其中包括比较不同化疗方案的有效性;对抑制剂的抵抗;耳鼻喉癌的后生变化以及后期和转移性胃食管癌的治疗方案。

标题 状态
1 A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety, and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast cancer 进行中(招募病人)
2 MK3475-394
A Phase III Randomized Double-Blind study of pembrolizumab plus best supportive care as second-line therapy in Asian subjects with previously systematically treated advanced hepatocellular carcinoma
进行中(招募病人)
3 Keynote-590
A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination of cisplatin and 5-fluorouracil versus placebo in combination with cisplatin and 5-fluorouracil as first-line treatment in subjects with advanced/metastatic esophageal carcinoma
进行中(停止招募病人)
4 Tessa FF01:
A Multicentre, Randomised, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr virus-specific Autologous Cytotoxic T Lymphocytes vs Gemcitabine andCarboplatin as first line treatment for Advanced NPC
进行中(停止招募病人)
5 MK3475-042:
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naive Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
进行中(停止招募病人)
6 CLEE011A2404
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribocliclib (LEE11) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease
进行中(停止招募病人)
7 EMR200095-006
Phase Ib/II Multicentre, Randomized Open Label Trial to Compare (MSC2156119J) Combined Gefitinib Versus Chemotherapy as Second Line Treatment in Subject with MET (+), Locally Advanced / Metastatic Non-Small Lung Cancer (NSCLC) Harbouring EGFR Mutation and Having Acquired Resistance to Prior EGFR-Tyrosine Kinase Inhibitor
进行中(停止招募病人)
8 CT10-01
Malaysian Cell Therapy Patient Registry: A Patient Registry (clinical database) to Evaluate the Health Outcomes of Patients who had received Cell Therapy In Malaysia
即将到来(CTA / 预算审查)
9 Studies On Epigenetic Changes In Nasopharyngeal Cancer 完成
10 Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer Care 完成
11 Healthcare Performance Measurement And Reporting For Breast Cancer Services In Malaysia 完成(View abstract) (View paper)
12 A Randomized, Phase II, Placebo Controlled Study Of Lacebo Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma 完成
13 A Randomized, 3 Arm, Multicentre, Phase III Study To Evaluate 完成
14 A Multiple Center, Open-Label, Randomized Phase III Study To Evaluate The Efficacy And Safety Of Erlotinib (Tarceva®) Versus Gemcitabine / Cisplatin As The First-Line Treatment For Stage IIIB / IV Non-Small Cell Lung Cancer (NSCLC) Patients With Mutations In The Tyrosine Kinase Domain Of Epidermal Growth Factor Receptor (EGFR) In Their Tumors. 完成
15 An Open-Label, Randomized Phase 3 Study Of The Efficacy And Tolerability Of Linifanib (ABT-869) Versus Sorafenib In Subjects With Advanced Hepatocellular Carcinoma (HCC) 完成

除了肿瘤学临床试验,来自其他卓越中心的顾问也通过发表研究论文为临床专业做出了重大贡献。以下是我们的顾问发表的研究成果(摘要、研究论文、海报等):

No 标题 顾问医生 刊物类型
1 Does A Picture Really Paint A Thousand Words? A Study On The Technical Qualities Of Online Aesthetic Oculofacial Clinical Photographs Dr Ong Chin Tuan
(Consultant Ophthalmologist)
Poster

如果您有兴趣并想了解更多关于这些正在进行的试验,请通过+603 7620 7979 ext 2854与我们联系,或者您可以给我们发邮件 info@beaconhospital.com.my 

搜寻医生